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Abstract
Functional amino acids (FAAs) and α-aminoamides (AAAs) are two classes of antiepileptic drugs
(AEDs) that exhibit pronounced anticonvulsant activities. We combined key structural
pharmacophores present in FAAs and AAAs to generate a new series of compounds and document
that select compounds exhibit activity superior to either the prototypical FAA (lacosamide) or the
prototypical AAA (safinamide) in the maximal electroshock (MES) seizure model in rats. A
representative compound, (R)-N-4′-((3″-fluoro)benzyloxy)benzyl 2-acetamido-3-
methoxypropionamide ((R)-10), was tested in the MES (mice, ip), MES (rat, po), psychomotor 6 Hz
(32 mA) (mice, ip), and hippocampal kindled (rat, ip) seizure tests providing excellent protection
with ED50 values of 13, 14, ~10 mg/kg, and 12 mg/kg, respectively. In the rat sciatic nerve ligation
model (ip), (R)-10 (12 mg/kg) provided an 11.2-fold attenuation of mechanical allodynia. In the
mouse biphasic formalin pain model (ip), (R)-10 (15 mg/kg) reduced pain responses in the acute and
the chronic inflammatory phases.
Epilepsy is a chronic disorder, characterized by recurrent, unprovoked seizures.1 A seizure is
defined as a discrete clinical event arising from transient, hypersynchronous, abnormal
neuronal behavior. Epilepsy, then, is not a disease but rather a syndrome arising from a group
of nonspecific, dysfunctional events in the brain. The treatment mainstay for patients with
epileptic disorders has been the long-term and consistent administration of anticonvulsant
drugs.2,3 There are more than 40 pharmacologic therapies used for the treatment of epilepsy.
4 Unfortunately, even when used optimally, these therapeutic interventions are ineffective for
some 30% of patients. 5 Moreover, their use is associated, in more than 40% of patients, with
untoward effects (e.g., drowsiness, dizziness, nausea, liver damage).6 The shortcomings of
current regimens highlight the need for new, more effective agents.
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We have previously reported that functionalized amino acids (FAAs,a 1)7–18 exhibit excellent
anticonvulsant activities in various animal seizure models. Whole-animal pharmacological
studies for 1 showed a unique profile, which indicated a novel mechanism of action. 7–19
Similarly, studies have demonstrated that α-aminoamides (AAAs, 2) provide superb seizure
protection. 20,21 Representative examples for each class of compounds have advanced through
clinical trials. Lacosamide ((R)-3),16 the 1 prototype, is a first-in-class antiepileptic drug (AED)
that was recently introduced in the United States and Europe for adjuvant treatment of partial-
onset seizures in adults.22 Safinamide ((S)-4) is a leading representative for 2. (S)-4 exhibited
excellent protection in seizure models, and positive responses have been reported in recent
phase III human clinical trials for the treatment of Parkinson disorders.21,23,24
Recent electrophysiology studies using cultured rat cortical neurons demonstrated that (R)-3
selectively enhanced sodium channel slow inactivation in a time- and voltage-dependent
manner, without affecting fast inactivation.25 Similarly, examination of (R)-3 with
recombinant NaV 1.3 and 1.7 voltage-gated sodium channels expressed in HEK293 cells and
of NaV1.8-type TTX-R currents from DRG neurons showed that (R)-3 selectively modulated
the slow inactivation state in each of these sodium channel subtypes.26 (R)-3 is the only reported
antiepileptic agent that selectively enhances slow inactivation without apparent interaction
with fast inactivation gating.
Patch-clamp, whole-cell electrophysiological studies using hippocampal neurons
demonstrated that (S)-4 inhibited tetrodotoxin-sensitive (TTX-S) fast Na+ currents in a
concentration-dependent manner.21a The inhibition was voltage dependent, showing an IC50
of ~100 uM when currents were stimulated from a resting condition, while stronger inhibition
(IC50 = 33 uM) was observed when sodium currents were stimulated from a −60 mV
depolarized membrane potential. Together, these findings indicated that (S)-4 exhibited a
higher affinity for the sodium channel’s inactivated state.24 Thus, the mechanisms associated
with sodium channel inhibition for (R)-3 and (S)-4 are different.
aAbbreviations: FAA, functionalized amino acids; AAA, α-aminoamides; AED, antiepileptic drug; TTX-S, tetrodotoxin-sensitive; MES,
maximal electroshock seizure; SAR, structure-activity relationship; IBCF, isobutylchloroformate; NMM, N-methyl morpholine; TBTU,
O-(benzotriazol-1-yl), N,N,N′,N′-tetramethyluronium tetrafluoroborate; DMTMM, 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-
methoxymorpholinium chloride; ASP, Anticonvulsant Screening Program; NINDS, National Institute of Neurological Disorders and
Stroke; scMet, subcutaneous Metrazol.
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At first glance, (R)-3 and (S)-4 appear structurally similar. Both have low molecular weights
((R)-3: MW =250; (S)-4: MW = 302 [free base]), each has a vicinal diamine backbone that
contains a carbonyl (C=O) moiety, and each has one chiral center. In addition, both compounds
contain an N-benzyl (PhCH2)–type substituent. Pharmacologically, both (R)-3 and (S)-4
exhibited excellent seizure protection16,19,27,28 in the maximal electroshock seizure (MES)
animal model,29 and electrophysiology studies demonstrated that both modulate sodium
currents.21a,25,26 Further inspection of (R)-3 and (S)-4 revealed stark differences in structure
and function. First, (R)-3 is neutral and (S)-4 is basic. Second, the (R)-3 sequence of atoms
attaches the N-benzyl moiety to an amide while in (S)-4 the substituted N-benzyl moiety
attaches to an amine. Third, there is a different structure-activity relationship (SAR) in the
MES test between the two classes of antiepileptic agents 1 and 2. For the 1 compounds, we
observed a steady improvement in activity as the C(2) position was changed from H and
CH2OH to CH3 to C6H5 to CH2OCH3.8,16 Correspondingly, for 2, activity in the MES test
increased as the C(2) position was changed from C6H5 to CH2OH to H to CH3.20 Fourth,
(R)-3 showed chiral specificity for function in the mouse (ip) (i.e., MES activity of (R)-3 vs
(S)-3 is >22:1),16 but (S)-4 did not (i.e., MES activity of (S)-4 ≈ (R)-4).20,30 Fifth, (S)-4
administration provided protection against several chemoconvulsants27 while (R)-3 did not.
19 Finally, (R)-3 enhanced the slow inactivation state of the voltage-gated sodium channel
thereby selectively blocking the activity of chronically depolarized neurons25,26 while (S)-4
inhibited TTX-S fast sodium currents.21a
The structural differences between (R)-3 and (S)-4 likely account for their different modes of
action and underscore that each compound has distinctive pharmacophores that contribute to
drug function. In this study, we asked whether key structural units in 1 and 2 could be
incorporated within a single compound to provide more effective anticonvulsant agents.31
Herein, we report the design, synthesis, and pharmacological evaluation of a series of




In generating I, we used the generalized structure II for 1 and III for 2 (Figure 1). Both II and
III include an “X-Y-Z” substituent at the N-benzyl 4′ site. “X-Y-Z” is a molecular unit 1–3
atoms long, or in the case I and III, it could also be a single bond. Our recent SAR study for
the N-benzyl 4′ site in (R)-3 showed that the introduction of select substituents at this position
provided compounds with excellent anticonvulsant properties.18 Similarly, the reported SAR
for 2 demonstrated that significant anticonvulsant activity was observed with various linkers
(“X-Y-Z”) at the N-benzyl position that bridged the two aromatic moieties in this agent.20 The
area of pharmacophore overlap in I is portrayed in the box, and this overlap permitted the
incorporation of key pharmacophores found in II (1) and III (2) within a unified structure
(Figure 1). For convenience, we divided I into three sectors: A, B, and C. Sector A is the
structural motif seen in II (1), sector B is the linker unit “X-Y-Z” reported in both II (1) and
III (2), and sector C is the terminal aromatic ring (Ar) found in III (2).
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Tables 1–3 lists the I compounds evaluated in this study. We prepared 20 compounds (5–22)
in which we varied the structural units in sectors A–C and the chirality of the C(2) center in
sector A. Since the number of structural permutations was large, we maintained the structural
pattern constancy for two sectors as we changed the other.
For compounds listed in Table 1, sector A was varied while we restricted sectors B and C to
an OCH2 and 3-(fluoro)phenyl moiety, respectively, to match (S)-4. Specifically, in this set of
compounds we evaluated key structural features important to the 1 SAR. We showed that 1
compounds containing a small R substituent provided excellent seizure protection in the MES
test and that anticonvulsant activity typically improved when a substituted heteroatom was
introduced one atom removed from the C(2) center. Moreover, anticonvulsant activity for the
1 compounds principally resided in the D-configuration.9,10,11,16,18 Thus, we progressively
increased the R substituent in 5–8 from hydrogen to methyl to isopropyl to tert-butyl and then
included in our selection list 9 and 10, compounds that contained a substituted heteroatom
positioned one atom removed from C(2). For compounds 6 and 10, we prepared the R- (D-
configuration) and the S- (L-configuration) stereoisomers to determine whether the
anticonvulsant activities for I mirrored those found for 1, in which a clear stereochemical
preference was observed,9–11,16,18 or that for 2, in which both stereoisomers displayed
comparable anticonvulsant activities.20,30 For all compounds listed in Table 1, except 5 and
9, we prepared I as a single stereoisomer. Compound 5 had no chiral center, and the synthetic
route for 9 provided the racemic mixture.
For compounds 10–19 listed in Table 2, we varied sector B’s “X-Y-Z” linker region and
employed the (R)-3 structural motif for sector A and the (S)-4 3-(fluoro)phenyl unit for sector
C. Following the SAR reported for (S)-4,20 we incorporated one, two, and three atom linkers
and varied the heteroatom content and degree of unsaturation of the linker. The choice of the
“X-Y-Z” unit was also consistent with the SAR reported for (R)-3,18 in which we showed that
incorporating select substituents (e.g., alkyl, substituted alkyl, vinyl, acetylenic, aryl) at the 4′
position of the N-benzyl ring gave compounds with superb seizure protection in the MES
test29 in rodents with some analogs having activities comparable with (R)-3 and established
AEDs.32
Finally, we evaluated the effect of the terminal aromatic ring by preparing compounds
(R)-10, and (R)-20–(R)-22 (Table 3). Here, we varied sector C to include the unsubstituted
aromatic compound (R)-20 and the three monofluorine–substituted regioisomers (R)-10,
(R)-21, and (R)-22 and set sector A to match (R)-3 and sector B to match (S)-4. We also prepared
compound 23, which contains the sector C structural motif found in many of our compounds.
Chemistry
Two similar routes were employed to prepare most I compounds in this study and depended
only on the C(2)-R substituent. For most I derivatives that incorporated the (R)-3 framework
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in sector A, we used a recently reported procedure to prepare 4′-substituted N-benzylamide
(R)-3 analogs18 beginning with either tert-Boc–protected (R)- or (S)-serine 24. The acid was
coupled with the desired benzylamine 25 using the mixed anhydride method
(isobutylchloroformate (IBCF), N-methyl morpholine (NMM)),33 unless otherwise indicated,
to give the N-benzyl amide 26 without racemization of the C(2) chiral center (Scheme 1).
Subsequent methylation of the serine hydroxy group (CH3I, Ag2O) gave ether 27. Deprotection
of the tert-butoxycarbonyl group with acid followed by acetylation of the amine with acetyl
chloride and triethylamine gave the desired product, I, in 43–80% yield. Using this method,
we prepared (R)-10, (S)-10, and (R)-11–(R)-22.
A similar procedure was used to prepare compounds 5, (R)-6–(R)-8 and (S)-6 (Scheme 2). We
began with a commercially available amino acid. Converting the amino acid to either the N-
acetyl (28, (R)-29, (S)-29) or the N-tert-butoxycarbonyl ((R)-30, (R)-31) derivative permitted
mixed anhydride coupling with benzylamine 32 to give the amides (5, (R)-6, (S)-6, (R)-33,
(R)-34). For (R)-33 and (R)-34 that were protected as the tert-Boc derivatives, acid deprotection
gave the amine, which was directly reacted with acetyl chloride and base to give (R)-7 and
(R)-8, respectively.
We developed a different route for the C(2) pyridyl derivative (R,S)-9 (Scheme 3). Beginning
with commercially available ethyl 2-(pyridin-2yl)acetate (35), basic hydrolysis provided acid
36, which was coupled with 4-(((3′-fluoro)benzyloxy)phenyl)methanamine (32) using O-
(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate (TBTU) to give 37.
Treatment of 37 with NaNO2 in acetic acid yielded the oximes 38 as an ~1:1 mixture of syn-
and anti-isomers. While oximes 38 could be separated by silica gel chromatography, the
mixture was reduced to amine 39 with Zn dust in the presence of ammonium formate and then
converted to racemic 9 with acetyl chloride and triethylamine.
The extended N-benzyl amide moiety within the I compounds was a key unit in our compounds.
Thus, we used a series of methods to construct this moiety (Schemes 4–6). For many of the
compounds, we reacted either 4-cyanophenol (40) with a substituted benzyl bromide (41–44)
or a (cyano)aryl bromide (52, 53) with the substituted phenol (54) or aryl-substituted alcohol
(55) under base conditions to give the ether (45–48, 56–58) (Scheme 4). Subsequent reduction
(LiAlH4) of the nitrile in 45–48 and 56–58 gave the requisite benzylamine (32, 49–51, 59–
61) for the mixed anhydride coupling reaction. We prepared nitrile 64 from 4-(hydroxy)
benzonitrile (40) and 3-(fluoro)phenethanol (62) using Mitsunobu coupling conditions34 and
then reduced nitrile 63 to benzylamine 64 with LiAlH4. Correspondingly, we reacted 4-(bromo)
benzonitrile (52) with 3-(fluoro)benzylamine (65) under Buchwald-Hartwig coupling
conditions38 to generate 66, which was reduced to amine 67 (Scheme 5). Finally, (R)-4-(iodo)
benzyl 2-acetamido-3-methoxypropionamide18 ((R)-69) served as the starting material for I
compounds (R)-11 and (R)-13–(R)-15 (Scheme 6). Coupling (R)-69 with 3-(fluoro)
phenylboronic acid (70) under Suzuki coupling conditions36 gave (R)-11. When trans-2-((3′-
fluoro)phenyl)vinylboronic acid (71) was substituted for 3-(fluoro)phenylboronic acid (70),
we obtained (R)-14 with an embedded trans-double bond. Reduction of (R)-14 (10% Pd/C,
H2) gave (R)-13. Sonogashira coupling37 of (R)-69 with 3-(fluoro)phenylacetylene (72)
afforded (R)-15. For (R)-17 synthesis, we coupled amine 67 with (R)-2-acetamido-3-
methoxypropanoic acid 17 ((R)-68) using 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-
methoxymorpholinium chloride (DMTMM)38 (Scheme 5).
The enantiopurity of (R)-6–(R)-8, (R)-10–(R)-22, (S)-6, and (S)-10 was assessed by the
detection of a single acetyl methyl signal in the 1H NMR spectrum for each compound when
a saturated solution of (R)-(−)-mandelic acid was added.39 In the cases of (R)-10-(R)-22, we
also observed a single O-methyl peak upon addition of (R)-(−)-mandelic acid.
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We report, in the Experimental Section, the details (synthetic procedure, characterization) of
the final step for all the compounds evaluated in the seizure models. In Supporting Information,
we provide a synthetic scheme for each compound tested and the experimental procedures used
and physical and full spectroscopic properties for all the synthetic compounds prepared in this
study.
Pharmacological Activity
Compounds 5, (R)-6–(R)-8, (R,S)-9, (R)-10–(R)-22, (S)-6, and (S)-10 were tested for
anticonvulsant activity at the Anticonvulsant Screening Program (ASP), which is part of the
National Institute of Neurological Disorders and Stroke (NINDS) at the U.S. National Institutes
of Health. Screening was performed using the procedures described by Stables and Kupferberg.
40 The pharmacological data from the MES test 29 are summarized in Tables 1–3 and similar
results obtained for (R)-3,16 (R)-4,30 (S)-4,30 and the clinical antiepileptic drugs (AEDs)
phenytoin,32 valproate,32 and phenobarbital32 are given in Table 1. All compounds were
administered intraperitoneally (ip) to mice and orally (po) to rats. Tables 1–3 lists the values
that were determined to be protective in blocking hind limb extension induced in the electrically
induced MES seizure model from the rodent identification studies. For compounds that showed
significant activity, we report the 50% effective dose (ED50) values obtained in quantitative
screening evaluations. Also provided are the median doses for 50% neurological impairment
(TD50) in mice, using the rotorod test,41 and the behavioral toxicity effects observed in rats.
42 TD50 values were determined for those compounds that exhibited significant activity in the
MES test. The protective index (PI = TD50/ED50) for each of these analogs is also listed. Select
compounds were also evaluated in the psychomotor 6 Hz (32 mA) seizure models (mice, ip).
43 When the I derivatives were evaluated in the subcutaneous Metrazol (scMet) seizure
model44 none provided protection at doses up to 300 mg/kg at two time points (0.5 and 4 h)
(data not shown). The absence of seizure protection in this assay is a hallmark of FAA activity
7–17 and contrasted with the data reported for (S)-4.27
The SAR data for I provided distinctive trends. In Table 1, we varied the C(2) R group in sector
A while maintaining the (S)-4 structural components found in sectors B and C. Using the mice
(ip) data, we observed that as the size of the C(2) alkyl group increased from methyl ((R)-6,
MES ED50 = >30, <100 mg/kg) to isopropyl ((R)-7, MES ED50 = >300 mg/kg) to tert-butyl
((R)-8, MES ED50 = >300 mg/kg), the anticonvulsant activity decreased. We also found that
MES seizure protection significantly increased upon the inclusion of a C(2)-substituted
heteroatom group one atom removed from the C(2) center ((R,S)-9, MES ED50 = 28 mg/kg;
(R)-10, MES ED50 = 13 mg/kg versus (R)-6, MES ED50 = >30, <100 mg/kg; (R)-7, MES
ED50 = >300 mg/kg; (R)-8, MES ED50 = >300 mg/kg). Similar SAR patterns were observed
for 1 compounds.7,11–14 Furthermore, for both 6 and 10, we tested the (R)- and (S)-enantiomers
and found that the principal activity resided in the (R)-stereoisomer (D-configuration) (MES
ED50 (mice, ip): (R)-6, >30, <100 mg/kg vs (S)-6, >100, <300 mg/kg, and (R)-10, 13 mg/kg
vs (S)-10, >300 mg/kg). Both the C(2) SAR pattern and the stereochemical preference for the
(R)-enantiomer for seizure protection strongly indicated that anticonvulsant activity in the MES
test for I compounds resembled the activity in 1 compounds. (R)-10 was the most active among
the sector A compounds, exhibiting an MES ED50 = 13 mg/kg. This placed (R)-10 midway
between phenytoin and phenobarbital in activity32 and approximately three times less active
than (R)-3.16 The protective index (PI = TD50/ED50) in mice (ip) for (R)-10 was 2, which was
lower than (R)-3 (PI = 5.2).16 When sector A I compounds were evaluated in the rat (po), the
effect of C(2) R substitution on MES seizure protection was less noticeable. In this model, we
found that (R)-10 (MES ED50 = 14 mg/kg) was more active than either 5 (MES ED50 = 31 mg/
kg) or (R)-6 (MES ED50 = 31 mg/kg) but that the glycine derivative 5 and the alanine analog
(R)-6 showed equal seizure protection. Interestingly, none of the three compounds displayed
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behavioral toxicity, even at doses up to 500 mg/kg. The activity observed for (R)-10 in the rat
(po) exceeded that of phenytoin and phenobarbital.32
Further SAR information was gathered by varying the sector B linker in I (Table 2). For these
compounds, we maintained the (R)-3 framework for sector A and the (S)-4 (3-fluoro)phenyl
substituent for sector C. We observed differences between the mice (ip) and rat (po) data sets.
In the mice, anticonvulsant activity in the MES test decreased as the linker changed from
CH2O ((R)-16) [MES ED50 = 5.9 mg/kg] to OCH2 ((R)-10) [MES ED50 = 13 mg/kg] to no
linker ((R)-11), O ((R)-12), CH2CH2 ((R)-13), N(H)CH2 ((R)-17) [MES ED50 = >10, <30 mg/
kg] to C(H)=C(H) ((R)-14), C≡C ((R)-15), CH2OCH2 ((R)-18), OCH2CH2 ((R)-19) [MES
ED50 = >30, <100 mg/kg]. Correspondingly, in the rat (po), we observed that the anticonvulsant
activity decreased by going from C≡C ((R)-15) [MES ED50 = 1.4 mg/kg], no linker ((R)-11)
[MES ED50 = 2.4 mg/kg], to O ((R)-12) [MES ED50 = <10 mg/kg], OCH2 ((R)-10) [MES
ED50 = 14 mg/kg], CH2O ((R)-16) [MES ED50 = 19 mg/kg], CH2CH2 ((R)-13) [MES ED50 =
<30 mg/kg] to C(H)=C(H) ((R)-14) [MES ED50 = ~30 mg/kg]. We were interested to find that
(R)-15 and (R)-11 exhibited superb seizure protection in the MES test (rat, po) with ED50 values
of 1.4 mg/kg and 2.4 mg/kg, respectively. Moreover, (R)-11 displayed no evidence of
behavioral toxicity at 500 mg/kg. Earlier, we reported the anticonvulsant activity of (R)-N-
(biphenyl-4-yl)methyl 2-acetamido-3-methoxypropionamide ((R)-73).18 (R)-73, like (R)-11,
exhibited outstanding seizure protection in the MES test (rat, po: MES ED50 = 2.0 mg/kg;
TD50 = 49 mg/kg) but, unlike (R)-11, was found to have noticeable neurotoxicity. The precise
role of the 3′-fluoro group in (R)-11 in modulating behavioral neurotoxicity is unclear but is
under investigation. Finally, for (R)-15 we not only observed excellent anticonvulsant
protection but also the duration of seizure protection extended for the entire 4 h testing period.
The activities of (R)-11 and (R)-15 exceeded (R)-3 (ED50 = 3.8 mg/kg)16 and other AEDs.32
Sector C’s terminal aryl group was the last structural unit evaluated (Table 3). For this series
of compounds, we maintained the (R)-3 framework for sector A, and the (S)-4 OCH2 unit for
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sector B since both moieties provided I compounds with excellent activity (Tables 1, 2). We
chose to evaluate the unsubstituted aryl compound, (R)-20 and the three mono-fluorophenyl
derivatives, (R)-10, (R)-21, and (R)-22. For the three fluorinated compounds, we observed in
mice (ip) that the 2″-fluoro derivative (R)-21 was the most active (MES ED50 = >3, <10 mg/
kg). Correspondingly, in the rat (po) model, the 4″-fluoro isomer (R)-22 was the most potent
(MES ED50 = 5.8 mg/kg) followed by the 2″-fluoro ((R)-21, MES ED50 = 11 mg/kg) and the
3″-fluoro ((R)-10, MES ED50 = 14 mg/kg) analogs. Removing the fluoro substituent to give
unsubstituted (R)-20 increased seizure protection (MES ED50 = <3 mg/kg) in mice (ip), making
this agent among the most potent I compounds tested under these conditions. Collectively,
these findings demonstrated that the terminal aryl ring in I can influence anticonvulsant
activities, thus warranting our further SAR exploration of this unit. We asked whether the
extended N-aryl substituent in I directly contributed to the observed anticonvulsant activity.
Accordingly, we evaluated 23 in the MES test (mice, ip) and observed modest anticonvulsant
activity (MES ED50 = >30, <100 mg/kg).
The excellent activity for (R)-10 warranted its further pharmacological evaluation in other
models. In the psychomotor 6 Hz (32 mA) seizure test,43 (R)-10 exhibited an ED50 = ~10 mg/
kg in mice (ip) (Table 1), a value comparable with that observed for (R)-3 (ED50 = 10 mg/kg).
19 In the sensitive rat (ip) hippocampal kindled seizure test,44,45 its ED50 value was 12 mg/kg.
This closely matched the value for (R)-3 (ED50 = 14 mg/kg) in similar screening.12 The
hippocampal kindled seizure assay is a model of partial complex seizures or temporal lobe
seizures, which are the most common and drug-resistant type of adult focal epilepsy.45a,46
Further evaluations of (R)-10 were undertaken using the sciatic nerve ligation model,47 which
is used to predict potential efficacy against chronic neuropathic pain in humans. Recent
pharmacological and clinical studies have documented that certain anticonvulsant compounds
are effective in several different models of inflammatory and neuropathic pain.48 Thus, it is
not surprising that these antiepileptic agents are also used to manage neuropathic pain. 48,49
Neuropathic pain results from excessive neuronal activity and damage resulting in dysfunction
of neuronal pathways within both the peripheral and the central nervous systems.48,49 The
sciatic ligation model was used to assess the efficacy of (R)-10 in rats. Using this test, we
showed that administration of (R)-10 (12 mg/kg; rats, ip) provided a 11.2-fold attenuation of
mechanical allodynia at 1 h.
The formalin test, a chemically induced biphasic pain model, was also employed.50 There are
two phases of response measured in the test, early (acute) and late (chronic inflammatory). The
acute phase results in a behavioral licking response, which is believed to be mediated by
chemical activation of local C-fibres.50 The late phase is likely due to the development of
peripheral inflammation and central sensitization of dorsal horn neurons. Thus, this model is
believed to provide preliminary information about the utility of the test candidate for the
treatment of acute and chronic inflammatory pain. When evaluated in the formalin model,
(R)-10 (15 mg/kg, mice, ip) significantly reduced the pain response in both the acute (35% of
control; p <0.01) and the late (44% of control; p <0.01) phases. These results compared
favorably with (R)-3, where comparable reduction in pain was observed only in the late phase
when 16 mg/kg was administered.51
In 5–22, we constructed compounds with the principal structural motif seen in 1 and then
extended the N-benzyl amide moiety to resemble 2. We briefly explored the reverse, where we
began with the 2 core structure and then incorporated at C(2) 1 units shown to have excellent
anticonvulsant activities. Accordingly, we prepared racemic 74 and 75 using the synthetic
procedures shown in Schemes 7 and 8, respectively. Compound 74 contained the (R)-3 (C)2-
methoxymethylene unit, and compound 75 had a 2-furanyl moiety. In the 1 series, racemic 3
and 88 displayed MES ED50 values (mice, ip) of 8.3 and 10 mg/kg, respectively (Table 4).
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When tested, (R,S)-74 and (R,S)-75 displayed good-to-moderate anticonvulsant activity in mice
(ip) ((R,S)-74, MES ED50 = 30–100 mg/kg; (R,S)-75, MES ED50 = 10–30 mg/kg), values that
were higher (lower activity) than observed for (R,S)-3 and (R,S)-88 in this test (MES ED50 =
8.3–10 mg/kg).11,16 Interestingly, we observed little or no activity in the scMet seizure model
for (R,S)-74 (scMet ED50 = >300 mg/kg) and (R,S)-75 (scMet ED50 = 100–300 mg/kg). This
finding contrasted with the excellent activity reported for (S)-4 in this model (scMet ED50 =
27 mg/kg).27 We concluded that the SAR guidelines for 17–16 did not help improve the
pharmacological activity of 2.
DISCUSSION
In this study, we combined key pharmacophores found in 1 and 2 to provide I, anticipating
that I might exhibit potent anticonvulsant activity. The structural design for I permitted the
near seamless overlap of the pharmacophores. Moreover, the structural economy gained from
this overlap permitted the design of a compact agent that conforms to Lipinski’s
pharmacokinetic rules for low molecular weight, oral therapeutic agents.52 We expected
several additional benefits from this design. First, the overlap eliminated the need for
extraneous bridging units, which could confound receptor binding and provide unwanted sites
for metabolism and toxicity. Second, we anticipated that I, like 1 and 2, 22,24 would exhibit
favorable CNS biodistribution.
We found that I did not prevent scMet-induced seizures in mice and that it showed a
stereochemical preference for function, which corresponds to the D-amino acid, in the MES-
induced seizure test in rodents. Moreover, anticonvulsant activity increased with placement of
a heteroatom one atom removed from the C(2) atom in I (Table 1) These whole animal
pharmacological responses are similar to those observed for 1 ((R)-3)7–18 but not 2 ((S)-4).
20,30 Table 2 shows that the most potent I derivatives in the MES test were those in which “X-
Y-Z” was a single bond ((R)-11), a rigid, linear unit ((R)-15), or a short moiety (i.e., O
((R)-12); “X-Y” [where X and Y are C(H), N(H), O, and CH2] ((R)-10, (R)-13, (R)-14,
(R)-16, (R)-17). Of these, (R)-11 and (R)-15 were the most potent anticonvulsants when tested
in the rat (po) (MES ED50 = 1.4–2.4 mg/kg).
The excellent anticonvulsant activity for several I compounds demonstrated that seizure
protection could be improved over their 1 counterpart by incorporating an extended N-aryl
substituent similar to that found in 2 ((S)-4). For example, in the MES test (mice, ip), the glycine
FAA 89 exhibited weak anticonvulsant activity (MES ED50 = >100, <300 mg/kg),8 but glycine
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5 exhibited a MES ED50 = >30, <100 mg/kg, mice (ip). When 5 was tested in the rat (po), the
MES ED50 = 31 mg/kg, and we observed no apparent neurological toxicity at doses of 500
mg/kg. Similarly, we found superb anticonvulsant activity for (R)-11 (MES ED50 = 2.4 mg/
kg) and (R)-15 (MES ED50 = 1.4 mg/kg) in the rat (po), which surpassed that of (R)-3 (MES
ED50 = 3.9 mg/kg). We evaluated 23 that contained the same extended N-benzyl substituent
that was incorporated in 5 and (R)-6–(R)-10 and observed only modest anticonvulsant activity
in mice (ip) (MES ED50 = >30, <100 mg/kg), indicating that this group alone was not
responsible for the observed seizure protection. Finally, we found that several I compounds
((R)-6, (R)-15) exhibited extended duration of action in the MES model in mice (ip) and rat
(po).
We tested (R)-N-4′-((3″-fluoro)benzyloxy)benzyl 2-acetamido-3-methoxypropionamide
((R)-10) in other neurological models. We first evaluated (R)-10 in two additional seizure
models. In the psychomotor 6 Hz (32 mA) test in mice (ip) 43 and the rat (ip) hippocampal
kindled seizure test,45 (R)-10 provided excellent protection, giving an ED50 of ~10 and 12 mg/
kg, respectively. Since several clinically available AEDs are used to treat pain disorders,48,
49 we evaluated (R)-10 in two animal pain models. When (R)-10 was tested at 12 mg/kg in the
sciatic nerve ligation model47 in rats (ip) we observed an 11.2-fold attenuation of mechanical
allodynia at 1 h. In the biphasic, chemically induced formalin pain model in mice,50 ip
administration of (R)-10 (15 mg/kg) reduced pain response in both the acute (35% of control)
and the late (44% of control) phases. These findings document the potential value of I to treat
a range of neurological conditions.
CONCLUSIONS
Our findings demonstrate that the incorporation of key pharmacophores in 1 and 2 to provide
I gave compounds of significant neurological interest. Using animal tests, we observed
excellent seizure protection and pronounced pain reduction. The pharmacological basis for I
anticonvulsant activity and pain protection has not been determined. Anticonvulsants, like
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many neurological agents,53 typically exert their activity through multiple pathways.54 Current
studies are directed at optimizing sectors A–C in I and evaluating these compounds in
electrophysiology, radioligand displacement, and functional assays to provide information
about the mode(s) of action of these novel hybrids.
EXPERIMENTAL SECTION
General Methods
The general methods used in this study were identical to those previously reported18 and are
summarized in the Supporting Information Section. All compounds were checked by
TLC, 1H and 13C NMR, MS, and elemental analyses. The analytical results are within +/−
0.40% of the theoretical value. The TLC, NMR and the analytical data confirmed the purity
of the products was ≥95%.
Preparation of N-4′-((3″-Fluoro)benzyloxy)benzyl 2-Acetamidoacetamide (5)
A THF solution (120 mL) of 28 (1.50 g, 12.8 mmol) was stirred and cooled at −78 °C under
Ar and then 4-methylmorpholine (NMM) (1.7 mL, 15.4 mmol) was added dropwise. After 2
min of stirring at this temperature, isobutylchloroformate (IBCF) (2.0 mL, 15.4 mmol) was
added dropwise leading to the precipitation of a white solid. The reaction was allowed to
proceed for additional 2 min and 32 (3.26 g, 14.1 mmol) was added portionwise at −78 °C.
The mixture was allowed to stir at room temperature (2 h), and then the white solid filtered
and the organic layer concentrated in vacuo. The solid was purified by flash column
chromatography on silica gel with methanol/EtOAc (0/10 -> 5/5) as the eluant to obtain 5 as
white solid (1.30 g, 31%): Rf = 0.11 (EtOAc); mp 155–156 °C; 1H NMR (CDCl3) δ 2.03 (s,
3H), 3.92 (d, J = 5.1 Hz, 3H), 4.38 (d, J = 5.7 Hz, 2H), 5.05 (s, 1H), 6.24–6.35 (br m, 2H),
6.92 (m, 2H), 6.97–7.04 (m, 1H), 7.11–7.21 (m, 4H), 7.30–7.38 (m, 1H); MS (M+H+)(ESI+)
331.1 [M + H+] (calcd for C18H19FN2O3H+ 331.1); Anal. (C18H19FN2O3•0.35 H2O): C, H,
F, N.
Preparation of (R)-N-4′-((3″-Fluoro)benzyloxy)benzyl 2-Acetamido-propionamide ((R)-6)
Employing the procedure to prepare 5 and using THF (100 mL), (R)-29 (1.50 g, 11.4 mmol),
NMM (1.5 mL, 13.7 mmol), IBCF (1.8 mL, 13.7 mmol), and 32 (2.90 g, 12.6 mmol) gave
(R)-6 that was purified by recrystallization (EtOAc) as a white solid (905 mg, 22%): Rf = 0.16
(EtOAc); mp 158 °C; [α]26.2D +27.3° (c 1, CHCl3); 1H NMR (CDCl3) δ 1.37 (d, J = 6.9 Hz,
3H), 1.94 (s, 3H), 4.32 (d, J = 5.7 Hz, 2H), 4.46–4.56 (m, 1H), 5.02 (s, 2H), 6.41 (d, J = 7.5
Hz, 1H), 6.79–6.85 (br m, 1H), 6.87–6.92 (m, 2H), 7.00 (td, J = 2.4, 8.4 Hz, 1H), 7.10–7.20
(m, 4H), 7.30–7.37 (m, 1H); MS (M+H+)(ESI+) 345.2 [M + H +] (calcd for
C19H21FN2O3H+ 344.2); Anal. (C19H21FN2O3): C, H, F, N.
Preparation of (S)-N-4′-((3″-Fluoro)benzyloxy)benzyl 2-Acetamidopropionamide ((S)-6)
Employing the procedure of (R)-6 and using (S)-29 (1.50 g, 11.4 mmol), NMM (1.5 mL, 13.7
mmol), IBCF, 32 (2.90 g, 12.6 mmol) gave after workup and recrystallization (EtOAc) a white
solid (1.50 g, 38%): Rf = 0.16 (EtOAc); mp 153–154 °C; [α]26.2D -28.1° (c 1, CHCl3); 1H NMR
(CDCl3) δ 1.38 (d, J = 7.2 Hz, 3H), 1.94 (s, 3H), 4.32 (d, J = 5.7 Hz, 2H), 4.46–4.57 (m, 1H),
5.02 (s, 2H), 6.38–6.46 (br d, 1H), 6.78–6.85 (br m, 1H), 6.89 (d, J = 8.4 Hz, 2H), 6.98–7.04
(m, 1H), 7.10–7.20 (m, 4H), 7.30–7.37 (m, 1H); MS (M+H+)(ESI+) 345.2 [M + H+] (calcd for
C19H21FN2O3H+ 345.2); Anal. (C19H21FN2O3): C, H, F, N.
Salomé et al. Page 11













Preparation of (R)-N-4′-((3″-Fluoro)benzyloxy)benzyl 2-Acetamido-3-methylbutanamide
((R)-7)
Trifluoroacetic acid (2 mL) was added to a CH2Cl2 (10 mL) solution of solution (R)-33 (1.00
g, 2.3 mmol) at 0 °C and the solution was stirred at room temperature (16 h). The reaction
solution was concentrated in vacuo, dried (30 min), and CH2Cl2 (20 mL) and a saturated
aqueous Na2CO3 solution (20 mL) were added. The layers were separated and the aqueous
layer was washed with CH2Cl2 (2 × 20 mL). The organic layers were combined and
concentrated under vacuum.
The residue was dissolved in CH2Cl2 (20 mL) and Et3N (0.49 mL, 3.5 mmol) and AcCl (200
μL, 2.8 mmol) were successively added at 0 °C. The mixture was stirred at room temperature
(3 h), aqueous 10% citric acid (60 mL) was added, and the organic layer was separated. The
aqueous layer was washed with CH2Cl2 (2 x 30 mL). All the organic layers were combined,
washed with aqueous saturated NaHCO3 (30 mL), and H2O (30 mL), dried (MgSO4), and
concentrated in vacuo. The solid was recrystallized with EtOAc to obtain (R)-7 (585 mg, 68%)
as a white solid: Rf = 0.26 (EtOAc); mp 199–200 °C; [α]25.2D +25.6° (c 0.5, MeOH); 1H NMR
(400 MHz, DMSO-d6) δ 0.81 (d, J = 3.0 Hz, 3H), 0.83 (d, J = 3.0 Hz, 3H), 1.87 (s, 3H), 1.90–
1.99 (m, 1H), 4.12–4.43 (dd, J = 6.4, 8.8 Hz, 1H), 4.19 (d, J = 5.8 Hz, 2H), 5.11 (s, 2H), 6.95
(d, J = 8.4 Hz, 2H), 7.11–7.19 (m, 3H), 7.24–7.28 (m, 2H), 7.39–7.46 (m, 1H), 7.87 (d, J =
8.8 Hz, 1H), 8.38 (t, J = 5.8 Hz, 1H); HRMS (M+Na+)(ESI+) 395.1747 [M + Na+] (calcd for
C21H25FN2O3Na+ 395.1747); Anal. (C21H25FN2O3): C, H, F, N.
Preparation of (R)-N-4′-((3″-Fluoro)benzyloxy)benzyl 2-Acetamido-3,3-dimethylbutanamide
((R)-8)
Employing a procedure similar to (R)-7 and using (R)-N-4′-((3″-fluoro)benzyloxy)benzyl 2-
amino-3,3-dimethylbutanamide (1.20 g, 3.3 mmol), CH2Cl2 (40 mL), Et3N (0.93 mL, 6.6
mmol), and AcCl (0.34 mL, 4.8 mmol) gave after workup and purification by flash column
chromatography on silica gel with EtOAc/hexanes (8/2 to 10/0) as the eluant (R)-8 as a white
solid (1.03 g, 81%): Rf = 0.56 (EtOAc); mp 64–66 °C; [α]27.0D -15.6° (c 1, CHCl3); 1H NMR
(400 MHz, CDCl3) δ 0.99 (s, 9H), 1.89 (s, 3H), 4.42 (1/2 ABq, J = 5.2, 14.4 Hz, 1H), 4.34–
4.40 (m, CH, 1H), 5.02 (s, 2H), 6.41 (br d, J = 8.8 Hz, 1H), 6.88 (d, J = 8.8 Hz, 2H), 6.85–
6.96 (br m, 1H), 7.00 (t, J = 8.4 Hz, 1H), 7.11–7.18 (m, 4H), 7.30–7.36 (m, 1H); HRMS (M
+Na+)(ESI+) 409.1903 [M + Na+] (calcd for C22H27FN2O3Na+ 409.1903); Anal.
(C22H27FN2O3): C, H, F, N.
Preparation of N-4′-((3″-Fluoro)benzyloxy)benzyl 2-Acetamido-2-(pyridin-2-yl)acetamide
((R,S)-9)
To a solution of 38 (1.81 g, 4.77 mmol, 1 equiv) in MeOH (95 mL) was added ammonium
formate (1.21 g, 19.08 mmol, 4 equiv) as a solid and then the reaction mixture was stirred at
room temperature (5 min). Zn dust (Sigma-Aldrich <10 micron, 1.20 g, 19.08 mmol, 4 equiv)
was added and the reaction heated at reflux (6 h), and then maintained at room temperature
(16 h). The reaction mixture was filtered through Celite®. The filtrate was concentrated and
the residue was dissolved in CH2Cl2 (100 mL). The CH2Cl2 layer was washed with a brine (2
× 100 mL), dried (Na2SO4), and concentrated in vacuo. The crude 39 was used without further
purification for the next step: Rf = 0.00 (EtOAc).
Compound 39 (4.77 mmol, 1 equiv) was dissolved in CH2Cl2 (100 mL) and then triethylamine
(0.8 mL, 5.72 mmol, 1.2 equiv) and AcCl (0.4 mL, 5.72 mmol, 1.2 equiv) were carefully added
at 0 °C and the resulting solution was stirred at room temperature (2 h). An aqueous saturated
NaHCO3 solution (100 mL) was added and the organic layer was extracted with CH2Cl2 (3 x
100 mL). The organic layers were combined, dried (Na2SO4), and concentrated in vacuo. The
residue was purified by chromatography on silica gel with EtOAc/hexanes (7/3 to 10/0) as the
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eluent. The residue was recrystallized (EtOAc) to obtain (R,S)-9 as a white solid (935 mg,
48%): Rf = 0.47 (EtOAc); mp 154–155 ºC; 1H NMR (CDCl3) δ 2.14 (s, 3H), 4.29–4.41 (m,
2H), 5.03 (s, 2H), 5.56 (d, J = 6.0 Hz, 1H), 6.87 (d, J = 9.0 Hz, 2H), 6.98–7.43 (m, 10H), 7.70
(dt, J = 1.6, 7.8 Hz, 1H), 8.50–8.52 (m, 1H); Anal. (C23H22FN3O3): C, H, F, N.
Preparation of (R)-N-4′-((3″-Fluoro)benzyloxy)benzyl 2-Acetamido-3-methoxypropionamide
((R)-10)
A saturated HCl solution in dioxane (1 mmol/2 mL, 21.75 mL) was added to (R)-N-4′-((3″-
fluoro)benzyloxy)benzyl 2-N-(tert-butoxycarbonyl)amino-3-methoxypropionamide (4.70 g,
10.9 mmol) at 0 °C and the solution was stirred at room temperature (4 h). The reaction solution
was concentrated in vacuo and dried (30 min).
Employing a procedure similar to (R)-7, and using the residue, CH2Cl2 (40 mL), Et3N (4.47
mL, 32.6 mmol), and AcCl (1.16 mL, 16.30 mmol) gave after workup and recrystallization
(EtOAc) (R)-10 (2.60 g, 65%) as a white solid: Rf = 0.29 (7/3 hexanes/EtOAc); mp 152 °C;
[α]24.5D -18.9° (c 1, CHCl3); 1H NMR (CDCl3) δ 2.03 (s, 3H), 3.37 (s, 3H), 3.43 (dd, J = 7.2,
9.0 Hz, 1H), 3.79 (dd, J = 3.9, 9.0 Hz, 1H), 4.40 (d, J = 5.7 Hz, 2H), 4.49–4.55 (m, 1H), 5.05
(s, 2H), 6.43 (br d, J = 7.2 Hz, 1H), 6.64–6.83 (br m, 1H), 6.89–7.05 (m, 3H), 7.10–7.22 (m,
4H), 7.31–7.38 (m, 1H); HRMS (M+H+)(ESI+) 375.1720 [M + H+] (calcd for
C20H23FN2O4H+ 375.1720); Anal. (C20H23FN2O4): C, H, F, N.
Preparation of (S)-N-4′-((3″-Fluoro)benzyloxy)benzyl 2-Acetamido-3-methoxypropionamide
((S)-10)
A saturated HCl solution in dioxane (1 mmol/2 mL, 20.8 mL) was added to (S)-N-4′-((3″-
fluoro)benzyloxy)benzyl 2-N-(tert-butoxycarbonyl)amino-3-methoxypropionamide (4.50 g,
10.4 mmol) at 0 °C and the solution was stirred at room temperature (4 h). The reaction solution
was concentrated in vacuo and dried (30 min).
Employing a procedure similar to (R)-7, and using the residue, CH2Cl2 (40 mL), Et3N (4.3
mL, 31.2 mmol), and AcCl (1.1 mL, 15.6 mmol) gave after recrystallization (EtOAc) (S)-10
(3.10 g, 80%) as a white solid: Rf = 0.29 (7/3 hexanes/EtOAc); mp 149–150 °C; [α]24.5D +18.8°
(c 1, CHCl3); 1H NMR (CDCl3) δ 2.02 (s, 3H), 3.36 (s, 3H), 3.43 (dd, J = 7.5, 9.1 Hz, 1H),
3.79 (dd, J = 4.2, 9.1 Hz, 1H), 4.40 (d, J = 5.7 Hz, 2H), 4.50–4.55 (m, 1H), 5.05 (s, 2H), 6.47
(br d, J = 6.0 Hz, 1H), 6.70–6.79 (br m, 1H), 6.90–7.05 (m, 3H), 7.10–7.22 (m, 4H), 7.31–7.38
(m, 1H); HRMS (M+H+)(ESI+) 375.1720 [M + H+] (calcd for C20H23FN2O4H+ 375.1720);
Anal. (C20H23FN2O4): C, H, F, N.
Preparation of (R)-N-(3″-Fluorobiphenyl-4-yl)methyl 2-Acetamido-3-methoxypropionamide
((R)-11)
To a flame-dried Schlenck tube, under Ar, containing a dioxane (22.5 mL) solution of
(R)-6918 (1.50 g, 4.0 mmol), palladiumtetrakis(triphenylphosphine) (464 mg, 0.402) and 3-
fluorophenylboronic acid (70) (670 mg, 4.80 mmol) was added an aqueous solution (9 mL) of
Cs2CO3 (2.60 g, 8.0 mmol). The mixture was stirred at reflux (16 h). Then MeOH and silica
gel were added, and the volatiles were concentrated in vacuo. The residue was purified by flash
chromatography on silica gel with EtOAc/MeOH (10/0 to 9/1) as the eluant to obtain (R)-11
(0.95 g, 60%) as a yellowish solid. To remove traces of palladium impurities, the solid was
treated with 6.00 g of resin scavenger (SPM32, PhosPhonics) in CH2Cl2. The mixture was
stirred at room temperature (2 h), filtered, and the filtrate evaporated under vacuum to obtain
800 mg (58%) of (R)-11 as a white solid: Rf = 0.22 (EtOAc); mp 170–172 °C; [α]25.3D = −8.1°
(c 0.5, CHCl3); 1H NMR (CDCl3) δ 2.03 (s, 3H), 3.39 (s, 3H), 3.47 (d, J = 7.5, 9.3 Hz, 1H),
3.81 (d, J = 3.9, 9.3 Hz, 1H), 4.45–4.55 (m, 2H), 4.56–4.63 (m, 1H), 6.53 (br d, J = 6.6 Hz,
1H), 6.93–7.07 (m, 2H), 7.23–7.51 (m, 5H), 7.53 (d, J = 8.1 Hz, 2H); HRMS (M+Cs+)(ESI+)
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477.0591 [M + Cs+] (calcd for C19H21FN2O3Cs+ 477.0587); Anal. (C19H21FN2O3): C, H, F,
N.
Preparation of (R)-N-4′-((3″-Fluoro)phenoxy)benzyl 2-N-Acetamido-3-methoxypropionamide
((R)-12)
A saturated HCl solution in dioxane (1 mmol/2 mL, 16.7 mL) was added to an Et2O (8 mL)
solution of (R)-N-4′-((3″-fluoro)phenoxy)benzyl 2-N-(tert-butoxycarbonyl)amino-3-
methoxypropionamide (3.50 g, 8.4 mmol) at 0 °C and the solution was stirred at room
temperature (16 h). The reaction solution was concentrated in vacuo and dried (30 min).
Employing a procedure similar to (R)-7, and using the residue, CH2Cl2 (40 mL), Et3N (3.52
mL, 25.1 mmol), and AcCl (0.91 mL, 12.5 mmol) gave after workup and purification by flash
column chromatography on silica gel with EtOAc as the eluant (R)-12 as a white solid (1.30
g, 43%): Rf = 0.45 (EtOAc); mp 125–126 °C; [α]25.3D –14.8° (c 1, CHCl3); 1H NMR (300
MHz, CDCl3) δ 2.04 (s, 3H), 3.39 (s, 3H), 3.45 (dd, J = 7.5, 9.3 Hz, 1H), 3.81 (dd, J = 4.2, 9.3
Hz, 1H), 4.45 (d, J = 6.0 Hz, 2H), 4.53–4.59 (m, 1H), 6.48 (br d, J = 6.0 Hz, 1H), 6.68 (dt, J
= 2.4, 10.2 Hz, 1H), 6.74–6.89 (m, 3H), 6.99 (d, J = 9.0 Hz, 2H), 7.21–7.34 (m, 3H); HRMS
(M+H+)(ESI+) 361.1564 [M + H+] (calcd for C19H21FN2O4H+ 361.1563); Anal.
(C19H21FN2O4): C, H, F, N.
Preparation of (R)-N-4′-((3″-Fluoro)phenethyl)benzyl 2-Acetamido-3-methoxypropionamide
((R)-13)
Pd/C (18 mg) was added to an EtOH solution of (R)-14 (180 mg, 0.49 mmol), and the mixture
was stirred at room temperature under H2 (1 atm) (36 h). The reaction mixture was filtered
through a pad of Celite®, and the pad was washed successively with EtOH and CH2Cl2. The
filtrate was concentrated under vacuum to obtain (R)-13 (170 mg, 94%) as a white solid: Rf =
0.29 (EtOAc); mp 134–136 °C; [α]24.4D = −12.3° (c 0.48, CHCl3); 1H NMR (400 MHz,
CDCl3) δ 2.03 (s, 3H), 2.90 (s, 4H), 3.38 (s, 3H), 3.43 (dd, J = 7.6, 9.2 Hz, 1H), 3.81 (dd, J =
4.0, 9.2 Hz, 1H), 4.40–4.47 (m, 2H), 4.50–4.55 (m, 1H), 6.41–6.47 (br m, 1H), 6.68–6.75 (br
m, 1H), 6.84–6.94 (m, 3H), 7.11–7.25 (m, 5H);HRMS (M+H+)(ESI+) 373.1927 [M + H+]
(calcd for C21H25FN2O3H+ 373.1927); Anal. (C21H25FN2O3•0.32H2O): C, H, N.
Preparation of (2-R,E)-N-4′-((3″-Fluoro)styryl)benzyl 2-Acetamido-3-methoxypropionamide
((R)-14)
To a flame-dried Schlenck tube, under Ar, containing a dioxane (22.5 mL) solution of
(R)-6918 (1.50 g, 4.0 mmol), palladiumtetrakis(triphenylphosphine) (464 mg, 0.402) and
trans-2-((3-fluoro)phenyl)vinylboronic acid (71) (800 mg, 4.82 mmol) was added an aqueous
solution (9 mL) of Cs2CO3 (2.60 g, 8.0 mmol). The mixture was stirred at reflux (16 h). Then,
MeOH and silica gel were added. The volatiles were concentrated in vacuo and the residue
was purified by flash chromatography on silica gel with EtOAc/MeOH (10/0 to 9/1) as the
eluant to obtain (R)-14 (0.90 g, 60%) as a yellowish solid. To remove traces of palladium
impurities, the solid was treated with 6.00 g of resin scavenger (SPM32, PhosPhonics) in
CH2Cl2. The mixture was stirred at room temperature (2 h), and filtered, the filtrate evaporated
under vacuum to obtain 560 mg (37%) of (R)-14 as a white solid: Rf = 0.53 (EtOAc); mp 206–
208 °C; [α]27D = −20.6° (c 0.5, CHCl3); 1H NMR (CDCl3) δ 2.04 (s, 3H), 3.40 (s, 3H), 3.40–
3.48 (m, 1H), 3.83 (d, J = 3.9, 8.7 Hz, 1H), 4.47–4.56 (m, 3H), 6.41–6.49 (br d, 1H), 6.75–
7.02 (br t, 1H), 6.92–7.01 (m), 7.07 (d, J = 2.7 Hz), 7.18–7.35 (m), 7.47 (d, J = 8.4 Hz) (10H);
LRMS (M+Na+)(ESI+) 393.1 [M + Na+] (calcd for C21H23FN2O3Na+ 393.1); Anal.
(C21H23FN2O3): C, H, F, N.
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Preparation of (R)-N-4′-(((3″-Fluoro)phenyl)ethynyl)benzyl 2-Acetamido-3-
methoxypropionamide ((R)-15)
To an anhydrous THF (70 mL) solution of (R)-6918 (2.60 g, 7.0 mmol) were sequentially added
triethylamine (0.95 mL, 14.0 mmol), 3-(fluoro)phenylacetylene (72) (1.20 ml, 10.37 mmol),
dichlorobis(triphenylphosphine)palladium (II) (491 mg, 0.70 mmol), and CuI (200 mg, 0.1.05
mmol) under Ar. The mixture was stirred at room temperature (16 h), and then MeOH and
silica gel were added. The volatiles were concentrated in vacuo and the residue was purified
by flash chromatography on silica gel with EtOAc/MeOH (9/1) as the eluant to obtain
(R)-15 (2.40 g, 93%) as a yellowish solid. To remove traces of palladium impurities, the solid
was treated with 21.00 g of resin scavenger (SPM32, PhosPhonics) in CH2Cl2. The mixture
was stirred at room temperature (2 h), and filtered, the filtrate evaporated under vacuum. The
solid was recrystallized with EtOAc to obtain 1.20 g (46%) of (R)-15 as a white solid: Rf =
0.26 (EtOAc); mp 200–202 °C; [α]24D = −2.6° (c 0.5, CHCl3); 1H NMR (DMSO-d6) δ 1.88
(s, 3H), 3.27 (s, 3H), 3.48–3.57 (m, 2H), 4.33 (d, J = 6.1 Hz, 2H), 4.45–4.53 (m, 1H), 7.25–
7.32 (m, 3H), 7.38–7.53 (m, 5H), 8.13 (d, J = 6.3 Hz, 1H), 8.56 (br t, J = 6.1 Hz, 1H); HRMS
(M+H+)(ESI+) 369.1614 [M + H+] (calcd for C21H21FN2O3H+ 369.1614); Anal.
(C21H21FN2O3): C, H, F, N.
Preparation of (R)-N-4′-(((3″-Fluoro)phenoxy)methyl)benzyl 2-Acetamido-3-
methoxypropionamide ((R)-16)
A saturated HCl solution in dioxane (1 mmol/2 mL, 10.2 mL) was added to (R)-N-4′-(((3″-
fluoro)phenoxy)methyl)benzyl 2 -N-(tert-butoxycarbonyl)amino-3-methoxypropionamide
(2.20 g, 5.1 mmol) at 0 °C and the solution was stirred at room temperature (2 h). The reaction
solution was concentrated in vacuo and dried (30 min) to provide (R)-2-amino-N-4′-(((3″-
fluoro)phenoxy)methyl)benzyl-3-methoxypropionamide hydrochloride as a white solid (1.80
g, quant.).
Employing a procedure similar to (R)-7, and using triethylamine (1.5 mL, 5.2 mmol), acetyl
chloride (380 μL, 10.7 mmol), CH2Cl2 (20 mL), and (R)-N-4′-(((3″-fluoro)phenoxy)methyl)
benzyl 2-amino-3-methoxypropionamide hydrochloride (1.30 g, 3.5 mmol) gave after workup
and recrystallization (EtOAc) (R)-16 (900 mg, 68%) as a white solid: Rf = 0.18 (EtOAc); mp
140–142 °C; [α]26.9D -21.0° (c 1, CHCl3); 1H NMR (CDCl3) δ 2.04 (s, 3H), 3.41 (s, 3H), 3.43
(dd, J = 7.5, 9.2 Hz, 1H), 3.82 (dd, J = 3.9, 9.2 Hz, 1H), 4.47–4.59 (m, 3H), 5.03 (s, 2H), 6.38–
6.43 (br d, 1H), 6.64–6.78 (m, 4H), 7.14–7.30 (m, 3H), 7.40 (d, J = 8.4 Hz, 2H); LRMS (M
+Na+)(ESI+) 397.1 [M + Na+] (calcd for C20H23FN2O4H+ 397.1); Anal. (C20H23FN2O4): C,
H, F, N.
Preparation of (R)-N-4′-((3″-Fluoro)benzylamino)benzyl 2-Acetamido-3-
methoxypropionamide ((R)-17)
Compound 67. HCl (293 mg, 1.1 mmol) was added to a THF (10 mL) solution of the (R)-68
(161 mg, 1.0 mmol) and the mixture was stirred at room temperature (5 min) and then NMM
(121 μL, 1.1 mmol) was added. The mixture was stirred at room temperature (5 min) and
DMTMM (332 mg, 1.2 mmol) was added, and the mixture was stirred at room temperature
(16 h). The white precipitate was filtered and the filtrate was concentrated in vacuo. The residue
was purified by flash column chromatography on silica gel with EtOAc/hexanes (5/5) to
EtOAc/acetone (5/5) as the eluant to obtain (R)-17 as a yellow solid (140 mg, 35%): Rf = 0.37
(EtOAc); mp 78–81 °C; [α]26.9D −15.0° (c 0.5, CHCl3); 1H NMR (CDCl3) δ 2.03 (s, 3H), 3.36
(s, 3H), 3.40 (dd, J = 7.2, 9.0 Hz, 1H), 3.82 (dd, J = 4.2, 9.0 Hz, 1H), 4.12–4.19 (br m, 1H),
4.31–4.37 (m, 4H), 4.46–4.52 (m, 1H), 6.38–6.45 (br m, 1H), 6.57 (d, J = 9.0 Hz, 3H), 6.91–
6.89 (m, 1H), 7.05–7.15 (m, 4H), 7.27–7.34 (m, 1H); HRMS (M+H+)(ESI+) 374.1880 [M +
H+] (calcd for C20H24FN3O3H+ 374.1879).
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Preparation of (R)-N-4′-(((3″-Fluoro)benzyloxy)methyl)benzyl 2-Acetamido-3-
methoxypropionamide ((R)-18)
A saturated HCl solution in dioxane (1 mmol/2 mL, 1.2 mL) was added to (R)-N-4′-(((3″-
fluoro)benzyloxy)methyl)benzyl 2-N-(tert-butoxycarbonyl)amino-3-methoxypropionamide
(1.10 g, 5.8 mmol) at 0 °C and the solution was stirred at room temperature (16 h). The reaction
solution was concentrated in vacuo and dried (30 min).
Employing a procedure similar to (R)-7, and using the residue, CH2Cl2 (20 mL), Et3N (1.40
mL, 9.8 mmol), and AcCl (356 μL, 4.9 mmol) gave after workup and recrystallization (EtOAc)
(R)-18 (450 mg, 47%) as a white solid: Rf = 0.26 (EtOAc); mp 140–142 °C; [α]25.2D −21.0°
(c 0.5, CHCl3); 1H NMR (CDCl3) δ 2.04 (s, 3H), 3.39 (s, 3H), 3.43 (dd, J = 7.8, 9.0 Hz, 1H),
3.82 (dd, J = 3.9, 9.0 Hz, 1H), 4.48 (d, J = 6.0 Hz, 2H), 4.48–4.56 (m, 1H), 4.54 (s, 2H), 4.55
(s, 2H), 6.42 (br d, J = 6.6 Hz, 1H), 6.71–6.79 (br t, 1H), 6.96–7.15 (m, 3H), 7.24–7.35 (m,
5H); Anal. (C21H25FN2O4): C, H, F, N.
Preparation of (R)-N-4′-((3″-Fluoro)phenethoxy)benzyl 2-N-Acetamido-3-
methoxypropionamide ((R)-19)
A saturated HCl solution in dioxane (1 mmol/2 mL, 10.0 mL) was added to an Et2O (5 mL)
solution of (R)-N-4′-((3″-fluoro)phenethoxy)benzyl 2-N-(tert-butoxycarbonyl)amino-3-
methoxypropionamide (2.20 g, 5.0 mmol) at 0 °C and the solution was stirred at room
temperature (16 h). The reaction solution was concentrated in vacuo and dried (30 min).
Employing a procedure similar to (R)-7, and using the residue, CH2Cl2 (30 mL), Et3N (2.1
mL, 15.0 mmol), and AcCl (0.54 mL, 7.5 mmol) gave after workup and recrystallization
(EtOAc) (R)-19 as a white solid (1.30 g, 66%): Rf = 0.28 (EtOAc); mp 147–148 °C; [α]25.2D
−16.6° (c 0.5, CHCl3); 1H NMR (400 MHz, CDCl3) δ 2.02 (s, 3H), 3.08 (t, J = 7.1 Hz, 2H),
3.36 (s, 3H), 3.39–3.44 (m, 1H), 3.79 (dd, J = 4.8, 9.6 Hz, 1H), 4.15 (t, J = 7.1 Hz, 2H), 4.33–
4.44 (m, 2H), 4.49–4.54 (m, 1H), 6.44 (br d, J = 6.4 Hz, 1H), 6.65–6.73 (br t, 1H), 6.84 (d, J
= 8.0 Hz, 2H), 6.90–7.06 (m, 3H), 7.16 (d, J = 8.0 Hz, 2H), 7.23–7.29 (m, 1H); HRMS (M
+Na+)(ESI+) 411.1696 [M + H+] (calcd for C21H25FN2O4Na+ 411.1697); Anal.
(C21H25FN2O4): C, H, F, N.
Preparation of (R)-N-4′-(Benzyloxy)benzyl 2-N-Acetamido-3-methoxypropionamide ((R)-20)
A saturated HCl solution in dioxane (1 mmol/2 mL, 24.1 mL) was added to an Et2O (10 mL)
solution of (R)-N-4′-(benzyloxy)benzyl 2-N-(tert-butoxycarbonyl)amino-3-
methoxypropionamide (5.00g, 12.1 mmol) at 0 °C and the solution was stirred at room
temperature (16 h). The reaction solution was concentrated in vacuo and dried (30 min).
Employing a procedure similar to (R)-7, and using the residue, CH2Cl2 (60 mL), Et3N (5.1
mL, 36.3 mmol), and AcCl (1.4 mL, 18.8 mmol) gave after workup and recrystallization
(EtOAc) (R)-20 as a white solid (2.60 g, 60%): Rf = 0.28 (EtOAc); mp 149 °C; [α]25.1D −26.8°
(c 0.5, CHCl3); 1H NMR (400 MHz, CDCl3) δ 2.02 (s, 3H), 3.36 (s, 3H), 3.39–3.44 (br m,
1H), 4.02–3.79 (dd, J = 4.2, 9.4 Hz, 1H), 4.36–4.44 (m, 2H), 4.48–4.55 (m, 1H), 5.05 (s, 2H),
6.42 (br d, J = 6.0 Hz, 1H), 6.64–6.71 (br m, 1H), 6.93 (d, J = 7.8 Hz, 2H), 7.18 (d, J = 7.8 Hz,
2H), 7.29–7.44 (m, 5H); HRMS (M+Na+)(ESI+) 379.1634 [M + Na+] (calcd for
C20H24N2O4Na+ 379.1634); Anal. (C20H24N2O4): C, H, N.
Preparation of (R)-N-4′-((2″-Fluoro)benzyloxy)benzyl 2-Acetamido-3-methoxypropionamide
((R)-21)
A saturated HCl solution in dioxane (1 mmol/2 mL, 11.57 mL) was added to (R)-N-4′-((2″-
fluoro)benzyloxy)benzyl 2-N-(tert-butoxycarbonyl)amino-3-methoxypropionamide (2.50 g,
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5.8 mmol) at 0 °C and the solution was stirred at room temperature (16 h). The reaction solution
was concentrated in vacuo and dried (30 min).
Employing a procedure similar to (R)-7, and using the residue (1.70 g, 5.1 mmol), CH2Cl2 (20
mL), Et3N (2.10 mL, 15.3 mmol), and AcCl (550 μL, 7.6 mmol) gave after workup and
recrystallization (EtOAc) (R)-21 (1.25 g, 65%) as a white solid: Rf = 0.28 (EtOAc); mp 173–
174 °C; [α]24.6D −20.7° (c 1, CHCl3); 1H NMR (400 MHz, CDCl3) δ 2.03 (s, 3H), 3.37 (s,
3H), 3.42 (dd, J = 7.6, 9.0 Hz, 1H), 3.79 (dd, J = 4.0, 9.0 Hz, 1H), 4.34–4.44 (m, 2H), 4.49–
4.54 (m, 1H), 5.12 (s, 2H), 6.43 (br d, J = 6.4 Hz, 1H), 6.66–6.72 (br t, 1H), 6.94 (d, J = 8.0
Hz, 2H), 7.06–7.21 (m, 4H), 7.28–7.34 (m, 1H), 7.49 (td, J = 1.6, 7.6 Hz, 1H); HRMS (M
+H+)(ESI+) 375.1720 [M + H+] (calcd for C20H23FN2O4H+ 375.1720); Anal.
(C20H23FN2O4): C, H, F, N.
Preparation of (R)-N-4′-((4″-Fluoro)benzyloxy)benzyl 2-Acetamido-3-methoxypropionamide
((R)-22)
A saturated HCl solution in dioxane (1 mmol/2 mL, 11.57 mL) was added to (R)-N-4′-((4″-
fluoro)benzyloxy)benzyl 2-N-(tert-butoxycarbonyl)amino-3-methoxypropionamide (2.50 g,
5.8 mmol) at 0 °C and the solution was stirred at room temperature (16 h). The reaction solution
was concentrated in vacuo and dried (30 min).
Employing a procedure similar to (R)-7, and using the residue (1.85 g, 5.6 mmol), CH2Cl2 (30
mL), Et3N (2.36 mL, 16.8 mmol), and AcCl (608 μL, 8.4 mmol) gave after workup and
recrystallization (EtOAc) (R)-22 (1.28 g, 61%) as a white solid: Rf = 0.22 (EtOAc); mp 166–
167 °C; [α]25.2D −19.4° (c 1, CHCl3); 1H NMR (400 MHz, CDCl3) δ 2.03 (s, 3H), 3.37 (s,
3H), 3.42 (dd, J = 7.6, 9.4 Hz, 1H), 3.79 (dd, J = 4.0, 9.4 Hz, 1H), 4.40 (d, J = 5.2 Hz, 2H),
4.49–4.54 (m, 1H), 5.01 (s, 2H), 6.40 (br d, J = 5.6 Hz, 1H), 6.62–6.69 (br t, 1H), 6.92 (d, J =
8.8 Hz, 2H), 7.07 (t, J = 8.8 Hz, 2H), 7.18 (d, J = 8.0 Hz, 2H), 7.37–7.41 (m, 2H); HRMS (M
+H+)(ESI+) 375.1720 [M + H+] (calcd for C20H23FN2O4H+ 375.1720); Anal.
(C20H23FN2O4): C, H, F, N.
Preparation of N-4′-((3″-Fluoro)benzyloxy)benzyl Acetamide (23)
Employing a procedure similar to (R)-7, and using 4-((3′-fluoro)benzyloxy)benzylamine (32)
(1.00 g, 4.3 mmol), CH2Cl2 (40 mL), Et3N (728 μL, 5.2 mmol), and AcCl (376 μL, 5.2 mmol)
gave after workup and trituration (Et2O) 23 (810 mg, 69%) as a white solid: Rf = 0.39 (EtOAc);
mp 131–132 °C; 1H NMR (400 MHz, DMSO-d6) δ 1.84 (s, 3H), 4.16 (d, J = 5.6 Hz, 2H), 5.11
(s, 2H), 6.95 (d, J = 8.8 Hz, 2H), 7.11–7.18 (m, 3H), 7.24–7.29 (m, 2H), 7.40–7.45 (m, 1H),
8.21–8.24 (br t, 1H); HRMS (M+Na+)(ESI+) 296.1063 [M + Na+] (calcd for
C16H16FNO2Na+ 296.1062); Anal. (C16H16FNO2): C, H, F, N.
Preparation of 2-(4′-((3″-Fluoro)benzyloxy)benzyl)amino-3-methoxypropionamide (74)
A solution of 79 (1.50 g, 4.32 mmol) in NH3 (7 N in MeOH, 150 mL) was stirred at room
temperature in a sealed tube (7 d). The solution was concentrated in vacuo, and the residue was
recrystallized (EtOAc) to obtain 74 as a white solid (350 mg, 24%): Rf = 0.25 (EtOAc); mp
84–85 °C; 1H NMR (300 MHz, CDCl3) δ 3.31–3.36 (m, 4H), 3.60 (d, J = 5.7 Hz, 2H), 3.71
(½ ABq, J = 12.9 Hz, 1H), 3.78 (½ ABq, J = 12.9 Hz, 1H), 5.06 (s, 2H), 5.40–5.44 (br s, 1H),
7.10 (d, J = 9.0 Hz, 2H), 6.96–7.05 (br dt, 1H), 7.13–7.25 (m, 4H), 7.31–7.38 (m, 1H); Mr
(+ESI) 355.16 [M+Na]+ (calcd for C18H21FN2O3Na+ [M+355.14]+). Anal. (C18H21FN2O3):
C, H, F, N.
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Preparation of 2-(4′-((3″-Fluoro)benzyloxy)benzyl)amino-2-(furan-2-yl)acetamide Oxalate
(75)
A solution of 87 (880 mg, 0.05 mmol) in NH3 (7 N in MeOH, 88 mL) was stirred at 4 °C (16
h). The solution was concentrated in vacuo, and the residue was dissolved in THF (2.3 mL) to
obtain a 1 N solution. To this solution, oxalic acid (2 N in THF, 4.6 mL) was added. After
standing at room temperature (16 h) the precipitate was collected, dried, and recrystallized with
i-PrOH. The white solid was recrystallized (absolute EtOH) to obtain 75 as a white solid (520
mg, 51%): Rf = 0.15 (EtOAc); mp 194–195 °C; 1H NMR (DMSO-d6) δ 3.75 (s, 2H), 4.54 (s,
1H), 5.14 (s, 2H), 6.44–6.45 (m, 1H), 6.48–6.50 (m, 1H), 7.51 (d, J = 9.0 Hz, 2H), 7.03–7.19
(m, 1H), 7.26–7.31 (m, 3H), 7.41–7.51 (m, 2H), 7.71–7.73 (m, 2H); Mr (+ESI) 355.13 [M
+H]+ (calcd for C22H21FN2O7H+ 355.15 [M+H]+). Anal. (C22H21FN2O7): C, H, F, N.
Pharmacology
Compounds were screened under the auspices of the National Institutes of Health’s
Anticonvulsant Screening Program. Experiments were performed in male rodents [albino
Carworth Farms No. 1 mice (intraperitoneal route, ip), albino Spague-Dawley rats (oral route,
po)]. Housing, handling, and feeding were in accordance with recommendations contained in
the ‘Guide for the Care and Use of laboratory Animals’. Anticonvulsant activity was
established using the MES test,29 6 Hz,42 hippocampal kindled seizure,45 and the scMet test,
44 according to previously reported methods.16
Formalin Test50a
The formalin test involved injection of 0.5% formalin into the mouse hind paw. Injection leads
to a biphasic behavioral response characterized by licking of the affected paw. The number of
licks is measured as a proxy for perceived pain. The first phase is termed the “acute” phase,
and the second phase is termed the “inflammatory” phase. Each trial involved 16 animals, 8
controls given an ip injection of vehicle and 8 given the test compound at a specified dose. The
amount of time that each animal spends licking is monitored at 2 min intervals, and monitoring
continues for 45 min. Plots of time licking versus time provides a biphasic response and permits
the area under the curve (AUC) to be determined for each animal for the acute and inflammatory
phases. The AUC for each compound-treated animal is compared to the average result from
the control group, yielding an average percent of control (reported with the SEM and p value).
Partial Sciatic Ligation Model47
Rats are anesthetized with sodium pentobarbital and the depth of anesthesia monitored by their
response to a tail pinch and observation of the depth of respiration. After surgical exposure of
the sciatic nerve, the nerve is slightly elevated, and approximately one-third to one-half of the
nerve is tied off. Typically, the surgical procedure is done on the right side while a sham surgery
is performed on the left hind leg where the sciatic nerve is only exposed. After recovery (7 d),
the animals are tested for the development of mechanical allodynia. The animals are placed in
a bottomless plexiglass box placed on a wire mesh (1/4″) platform. After a 30–60 min
acclimation period, a baseline mechanical sensitivity is determined by applying a series of
calibrated Von Frey fibres perpendicularly to the plantar surface of each hind paw and holding
it in place for 6 sec with enough force to slightly bend the fibre. After a positive response
(withdrawal of the foot) is observed a weaker fibre is applied until a 50% threshold for
withdrawal can be determined. The allodynic threshold is then re-determined after ip
administration of the test compound. Testing is conducted at the time-to-peak effect of the
compound in the MES test.
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Overlay of Pharmacophores in I
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General Procedure for the Preparation of (R)- and (S)-N-(4′-Substituted)benzyl 2-
Acetamido-3-methoxypropionamide Derivatives I
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General Procedure for the Preparation of (R)- and (S)-N-(4′-(3-fluorobenzyloxy)benzyl)benzyl
2-Acetamido-2-(substituted)-acetamide Derivatives 5–8
Salomé et al. Page 25














Preparation of N-(4-(3-Fluorobenzyloxy)benzyl) 2-Acetamido-2-(pyridin-2-yl)acetamide
((R,S)-9)
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Benzylamine 32, 49–51, 59–61, and 64 Synthesis
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Benzylamine 67 and Compound (R)-17 Synthesis
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Preparation of Compounds (R)-11, (R)-13, (R)-14 and (R)-15
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Table 4
Pharmacological Data for α-Aminoamide Derivatives 74 and 75 and their Functionalized Amino Acid
Counterparts 3 and 88a
No. R4
Mice (ip)b
MES,c ED50 Tox,d TD50 PI e
(R,S)-74 >30, <100 [0.5] >100, <300 [0.5]






(R,S)-88g 10 (9.1–12) ~40 ~4.0
(S)-4h 8.0 (7.0–9.1) 630 (560–700) 78

















The compounds were tested through the auspices of the NINDS ASP.
b
The compounds were administered intraperitoneally. ED50 and TD50 values are in milligrams per kilogram.
c
MES = maximal electroshock seizure test.
d
TD50 value determined from the rotorod test.
e
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